Pulse Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Pulse Biosciences filed an amendment to its 2025 Annual Report to provide required disclosures regarding corporate governance, executive compensation, and director information.
NASDAQ
Pulse Biosciences' 2025 Annual Report details significant progress in its Nano-pulse Stimulation (NPS) technology for atrial fibrillation and soft tissue ablation, alongside continued operating losses and plans for future capital raises.
NASDAQ
10-K/A: Pulse Biosciences Files Amendment to 10-K, Discloses Executive Changes and Compensation Details
Pulse Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, and corporate governance.
NASDAQ
10-K: Pulse Biosciences Reports 2024 Results, Focuses on Atrial Fibrillation and Soft Tissue Ablation
Pulse Biosciences' 2024 10-K filing highlights a strategic shift towards atrial fibrillation and soft tissue ablation, with ongoing clinical trials and regulatory clearances for its Nano-pulse Stimulation (NPS) technology.
NASDAQ
Pulse Biosciences files its annual 10-K report, detailing executive compensation changes, financial performance, and risk factors, while also amending employment agreements for key executives.